MedTrace Logo

Increasing Uptake of Colorectal Cancer Screening in Ontario

NCT01629004 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5155

Last updated 2014-12-23

No results posted yet for this study

Summary

The investigators hope to determine whether the addition of an FOBT kit and educational materials to a second mailed invitation compared to a second mailed invitation alone increases use of appropriate screening tests (FOBT for average risk or colonoscopy if increased risk) by eligible persons within 6 months of the second mailing in: (1)Non-responders to an initial mailed CRC screening invitation from their family physician and, (2)Those who responded to the initial mailed CRC screening invitation and are due for repeat screening (i.e., "recall" patients). In addition, the investigators will also explore the impact of the investigators intervention in likely under-screened groups such as those living in more remote areas of the province and those with low socio-economic status as well as assessing the cost-effectiveness of this strategy.

Conditions

  • Colorectal Disorders

Interventions

OTHER

FOBT kit

Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.

OTHER

Mailed invitation

Mailed CRC screening invitation alone on behalf of family physician.

Sponsors & Collaborators

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Jill Tinmouth, MD · Sunnybrook HSC

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01629004 on ClinicalTrials.gov